EU drug firms to China: open up, streamline, protect and talk
This article was originally published in SRA
Lengthy delays in the approval of new drugs in China and inadequate protection of confidential data are among the main concerns in the latest policy position paper from the European Union Chamber of Commerce in the country1.
You may also be interested in...
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.